Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Parasite Inhibitor
Phosalone is an organophosphate insecticide that primarily targets acetylcholinesterase, leading to the inhibition of neurotransmission in parasites. Its potent biological activity makes it effective in controlling a wide range of insect pests. Phosalone is utilized in entomological research and in studies focusing on pest management strategies and the biochemical pathways of insecticide resistance. -
Parasite Inhibitor
trans-Permethrin is a synthetic pyrethroid that primarily targets the nervous system of insects, functioning as a potent insecticide and neurotoxin. Its primary biological activity involves disrupting sodium channel function, leading to paralysis and death in targeted pest populations. This compound is widely used in research applications aimed at understanding insecticide resistance mechanisms and developing novel pest control strategies. -
Parasite Inhibitor
Bitoscanate, also known as p-Phenylene diisothiocyanate, primarily acts as a parasite inhibitor. It demonstrates significant activity against hookworms, making it valuable in the therapeutic management of parasitic infections. Its biological properties facilitate research applications focused on developing effective treatments for helminthic diseases. -
Parasite Inhibitor
CWHM-1552 is a potent inhibitor of Plasmodium falciparum, demonstrating IC50 values of 51 nM and 53 nM against the 3D7 and Dd2 strains, respectively. This compound exhibits significant efficacy in oral administration and is designed for research applications focused on malaria treatment and parasite biology. CWHM-1552 serves as a valuable tool for studying antimalarial mechanisms and developing novel therapeutic strategies. -
Parasite Inhibitor
Anticancer agent 140 is a compound designed as a parasite inhibitor, exhibiting significant potential for anticancer and antiparasitic activities. This reagent targets specific cellular pathways, making it valuable for research in cancer biology and parasitology. Its effectiveness in inhibiting parasite proliferation underscores its relevance in drug discovery and development for related diseases. -
SDH Inhibitor
Succinate dehydrogenase-IN-2 is a potent inhibitor targeting succinate dehydrogenase (SDH) with an IC50 value of 1.22 mg/L. This compound demonstrates significant antifungal activity, effectively inhibiting a range of fungal pathogens including S. sclerotiorum, V. mali, G. graminis, R. solani, and B. cinerea, with EC50 values in the range of 0.52-3.42 mg/L. It is a valuable tool for research applications focusing on fungal infections and metabolic pathways involving SDH. -
Parasite Inhibitor
Mirincamycin hydrochloride is a potent inhibitor of malaria, specifically targeting the early liver stages of Plasmodium. This compound demonstrates protective effects, effectively preventing the progression of the parasite during its initial infection phase. However, it is important to note that Mirincamycin does not eliminate dormant liver stages, as observed in studies utilizing a rhesus monkey model. This characteristic limits its applicability in certain therapeutic scenarios against malaria. -
Parasite Inhibitor
Allylpyrocatechol is a parasite inhibitor known for its antimalarial activity. This compound has been validated for its efficacy both in vitro and in vivo, demonstrating significant potential in combating malaria. Additionally, structure-activity relationship analyses of its analogs have been conducted, providing insights into the mechanisms underlying its biological effects. Its application in research can contribute to the development of novel antimalarial therapies. -
Parasite Inhibitor
BiPNQ is a potent inhibitor of Trypanosoma cruzi, the protozoan responsible for Chagas disease. This compound effectively disrupts the biological processes of the parasite, making it a valuable tool for research focused on the treatment of Chagas disease and the development of antiparasitic therapies. Its inhibitory activity may help elucidate the mechanisms of infection and potential therapeutic targets. -
Parasite Inhibitor
Ludaconitine, derived from Aconitum spicatum (Bruhl) Stapf, functions as a potent inhibitor of parasites. It demonstrates significant antileishmanial activity, exhibiting an IC50 of 36.10 μg/mL. This compound is valuable for research applications focused on leishmaniasis and the exploration of novel antiparasitic agents. -
Parasite Inhibitor
Ep vinyl quinidine, an epi-vinyl stereoisomer of Quinidine, serves as a targeted inhibitor of parasitic activity. This compound exhibits significant potential in malaria research, leveraging its capabilities as a selective cytochrome P450db inhibitor. Additionally, it functions as a potassium channel blocker with an IC50 of 19.9 μM, positioning it as a valuable tool for investigating anti-parasitic mechanisms and therapeutic interventions. -
Parasite Inhibitor
Antileishmanial agent-1 specifically targets Leishmania parasites, demonstrating potent inhibitory activity against L. amazonensis promastigotes with an IC50 of 15.52 μM and intracellular amastigotes with an IC50 of 4.10 μM. This compound is valuable for research focused on leishmaniasis treatment, facilitating studies on parasite bioenergetics and drug resistance mechanisms. Its ability to effectively inhibit parasite growth makes it a significant tool in the development of antileishmanial therapies. -
HCV Protease Inhibitor
MK-2748 is a potent inhibitor of the hepatitis C virus (HCV) NS3/4A protease. It demonstrates broad-spectrum antiviral activity across all genotypes (gt1a-gt6) with nanomolar potency (IC₅₀ < 0.115 nM), including strong efficacy against drug-resistant mutant strains such as gt1b R155K (IC₅₀ = 0.032 nM) and D168Y (IC₅₀ = 0.057 nM). MK-2748 is valuable for research on HCV infection and contributes to the understanding of antiviral mechanisms and treatment strategies. -
HCV Protease Inhibitor
AL-611 is an inhibitor of the Hepatitis C virus (HCV) NS5B polymerase, demonstrating potent activity with an EC50 value of 5 nM. This compound plays a critical role in antiviral research, particularly in the development of therapeutic strategies against HCV infections. Its effectiveness in inhibiting HCV replication makes it a valuable tool for studies focused on viral RNA synthesis and enzyme interactions. -
HCV Protease Inhibitor
GSK2818713 is a selective Hepatitis C virus (HCV) protease inhibitor that disrupts the replication complex associated with the NS5A protein. This compound exhibits potent anti-HCV activity, making it a valuable tool for studying the replication and life cycle of the virus. GSK2818713 is applicable in research focused on developing therapeutic strategies against Hepatitis C. -
HCV Protease Inhibitor
BI-1230 is a potent inhibitor of the HCV NS3 protease, exhibiting nanomolar activity in blocking viral replication. It demonstrates high selectivity against other serine and cysteine proteases, making it a valuable tool for studying hepatitis C virus infection mechanisms. Additionally, BI-1230 shows favorable pharmacokinetic properties, supporting its potential use in drug development and research applications related to antiviral therapy. -
HCV Protease Inhibitor
MK-6169 is a potent hepatitis C virus (HCV) protease inhibitor that targets the viral NS5A protein. It exhibits broad-spectrum activity against various HCV genotypes, making it a valuable tool for research on antiviral therapies in hepatitis C. This compound is useful for exploring the mechanisms of HCV replication and potential treatment strategies in pharmaceutical development. -
HCV Protease Inhibitor
Isoeuphorbetin is a dimeric coumarin that acts as a potent inhibitor of HCV protease, demonstrated by an IC50 value of 3.63 µg/mL. This compound has significant potential in antiviral research, particularly in the development of therapeutics targeting hepatitis C virus infection. Its ability to effectively block viral protease activity makes it a valuable tool for studying HCV biology and drug discovery. -
HCV Protease Inhibitor
Ac-D-DGla-LI-Cha-C is a potent inhibitor of the hepatitis C virus (HCV) protease, effectively disrupting viral replication. This peptide is instrumental in studying various biological processes and diseases, including cancer, autoimmune disorders, fibrotic conditions, inflammatory responses, neurodegenerative diseases, infectious diseases, lung and cardiovascular disorders, as well as metabolic diseases. Its targeted action on HCV protease makes it a valuable tool for research in virology and therapeutic development. -
HIV-1 Capsid Inhibitor
Lenacapavir is an HIV-1 capsid inhibitor that targets the interface between capsid hexamers and CA monomers, disrupting capsid assembly and viral maturation. This compound inhibits the nuclear translocation of HIV-1 DNA and interferes with CA-mediated protein-protein interactions, resulting in reduced formation of 2-LTR circles and pre-integration proviruses. Additionally, Lenacapavir induces aberrant capsids and decreases the production of mature HIV-1. It demonstrates efficacy against various HIV-1 subtypes and clinical isolates, making it a valuable reagent for research on HIV-1 infection. -
HIV-1 RT Inhibitor
Tenofovir diphosphate disodium is a potent inhibitor of HIV-1 reverse transcriptase, with a Ki value of 1.55 μM for DNA and 0.022 μM for RNA. This compound exhibits key biological activity as an antiretroviral agent, making it a valuable tool for the study of HIV and AIDS. It is suitable for research applications focused on understanding viral replication and developing therapeutic strategies against HIV infection. -
CCR5 Inhibitor
DAPTA is a synthetic peptide that acts as a selective inhibitor of the CCR5 receptor. By blocking CCR5, DAPTA interferes with viral entry into host cells, exhibiting significant anti-HIV activity. This compound is valuable for research in virology and the development of therapeutic strategies against HIV. -
HIV-1 Inhibitor
PYR01 is a non-nucleoside reverse transcriptase inhibitor that targets HIV-1 by activating the death of infected cells. It exhibits significant antiviral activity, demonstrating IC50 values of 27.5 nM and 39.7 nM for cytotoxic and antiviral effects, respectively. By promoting HIV-1 Gag-Pol dimerization and intracellular activation of HIV-1 protease, PYR01 induces selective cytotoxicity in HIV-1-infected cells. This compound is valuable for research focused on HIV biology and therapeutic strategies. -
HIV-1 Inhibitor
PF-3450074 is a specific inhibitor of the HIV-1 capsid protein (CA), exhibiting broad-spectrum antiviral activity against various HIV isolates with submicromolar potency (EC50=8-640 nM). This compound functions at an early stage of the HIV-1 life cycle, impeding viral replication by competing with the binding of nuclear host factors CPSF6 and NUP153. Additionally, PF-3450074 disrupts key processes such as uncoating, assembly, and reverse transcription, making it a valuable tool for HIV research. -
CD4-Targeted HIV Inhibitor
Cyclotriazadisulfonamide (CADA) is a selective inhibitor of HIV entry that targets CD4. It functions by inhibiting the co-translational translocation of human CD4 into the endoplasmic reticulum lumen in a signal peptide-dependent manner. In addition, CADA acts as a Sec61 translocon inhibitor, making it a valuable tool for studying HIV pathogenesis and potential therapeutic strategies against HIV infection. -
HIV-1 Inhibitor
Glycolithocholic acid 3-sulfate is a cholic acid derivative that serves as an effective HIV-1 inhibitor. It demonstrates the ability to inhibit the replication of HIV-1 in vitro, making it a valuable tool for studying HIV infection. Additionally, Glycolithocholic acid 3-sulfate may have relevance in research related to gallbladder disease. -
V-ATPase/HIV-1 Inhibitor
Diphyllin is a potent inhibitor of vacuolar H+-ATPase (V-ATPase) with an IC50 of 17 nM, and also acts as an HIV-1 inhibitor with an IC50 of 0.38 μM. This compound effectively disrupts the acidification of osteoclast lysosomes, leading to significant inhibition of osteoclast-mediated bone resorption while leaving osteoblastic bone formation unaffected. Diphyllin is valuable for investigating bone metabolism-related diseases and exploring therapeutic avenues for conditions characterized by excessive bone resorption. -
HIV Inhibitor
Censavudine is a nucleoside reverse transcriptase inhibitor that exhibits potent antiviral activity against HIV. With EC50 values ranging from 30 nM to 81 nM for HIV-2 and 450 nM to 890 nM for HIV-1, this compound is effective in disrupting viral replication. Additionally, Censavudine possesses a reactive alkyne group, allowing it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc), making it a versatile tool for click chemistry applications in drug development and molecular biology research. -
HIV/NRTTI Inhibitor
MK-8527 is an orally active inhibitor of HIV that functions as a nucleoside reverse transcriptase translocation inhibitor (NRTTI). This compound exhibits antiviral activity by impeding reverse transcriptase, an essential enzyme for viral replication. MK-8527 is primarily utilized in research focused on the development of HIV therapeutic strategies and studying mechanisms of resistance in retroviral infections. -
HIV Inhibitor
2',3'-Dideoxyadenosine is an inhibitor of HIV replication that functions by incorporating into viral DNA, thereby terminating chain elongation. This compound exhibits significant antiretroviral activity and is utilized in research to understand mechanisms of HIV infection and the development of therapeutic strategies against the virus. Its efficacy makes it a valuable tool in antiviral studies and drug development pipelines focused on HIV. -
HIV Inhibitor
Zingibroside R1 is a dammarane-type triterpenoid saponin that targets HIV through its inhibitory effects. Isolated from the rhizomes, taproots, and lateral roots of Panax japonicus C. A. Meyer, it demonstrates anti-HIV-1 activity, in addition to notable anti-tumor and anti-angiogenic properties. Zingibroside R1 also inhibits 2-deoxy-D-glucose (2-DG) uptake in EAT cells with an IC50 of 91.3 μM, highlighting its potential for further research in cancer and viral therapies. -
HIV Inhibitor
(R)-Edelfosine, also known as (R)-ET-18-OCH3, is an ether lipid analog that primarily targets HIV through its antiviral properties. This compound exhibits significant anti-HIV activity and demonstrates potential antineoplastic effects. It is commonly utilized in research applications related to antiviral therapies and cancer treatment investigations. -
HIV-1 reverse transcriptase Inhibitor
Ulonivirine is an orally active non-nucleoside inhibitor of HIV-1 reverse transcriptase, targeting the hydrophobic binding pocket adjacent to the enzyme's polymerase active site. It effectively disrupts viral replication, making it a valuable tool for research focused on HIV-1 infection and the mechanisms of antiretroviral resistance. Ulonivirine is suitable for studies aimed at understanding HIV-1 pathogenesis and developing therapeutic interventions. -
HIV-1 Integrase Inhibitor
Bictegravir sodium is a highly potent inhibitor of HIV-1 integrase, demonstrating an IC50 of 7.5 nM. This compound exhibits robust and selective anti-HIV activity while maintaining low cytotoxicity. Bictegravir sodium is primarily utilized in research focused on HIV treatment strategies and the development of antiretroviral therapies. -
HIV-1 Integrase Inhibitor
1-Butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide is a potent inhibitor of HIV-1 integrase, targeting both the 3'-processing and strand transfer stages of the integration process. This compound serves as a valuable tool in HIV-1 research, facilitating the study of viral replication and integration mechanisms. Its effectiveness in inhibiting key steps in the integration pathway makes it an important reagent for investigations related to HIV-1 therapeutic development. -
HIV-1 Inhibitor
BIT-225 is an HIV-1 inhibitor that specifically targets the Vpu protein by blocking its ion channel function. This mechanism effectively inhibits the release of HIV-1, particularly in monocyte-derived macrophages, with an EC50 of 2.25 μM. BIT-225 demonstrates a favorable safety profile, exhibiting minimal cytotoxicity (TC50 of 284 μM). This compound is valuable for research into therapeutic strategies for HIV-1. -
HIV Inhibitor
APOBEC3G-IN-1 is a potent inhibitor of the HIV virus that targets the APOBEC3G enzyme. This compound demonstrates significant activity in inhibiting viral replication, making it a valuable tool in HIV research. Its ability to modulate the immune response against HIV provides insights into viral pathogenesis and potential therapeutic strategies. -
Influenza Virus Inhibitor
Sodium copper chlorophyllin B is a sodium-copper complex of chlorophyll with demonstrated antiviral activity against the Influenza virus, exhibiting IC50 values between 50 to 100 μM. It also shows potential activity against HIV. This compound is primarily utilized in research applications aimed at understanding antiviral mechanisms and developing therapeutic strategies for viral infections. -
HIV-1 Nucleocapsid Protein Inhibitor
Claficapavir is a potent inhibitor of the HIV-1 nucleocapsid protein, specifically designed to interfere with its chaperone functions. With an IC50 of approximately 1 μM and a strong binding affinity (Kd = 20 nM), Claficapavir exhibits significant antiviral activity against HIV-1. This compound serves as a valuable tool for research focused on HIV pathogenesis and therapeutic interventions targeting viral replication. -
HIV-1 inhibitor
HIV-1 inhibitor-6 is a diheteroarylamide-based compound that functions as a potent inhibitor of HIV-1 pre-mRNA alternative splicing. This compound effectively blocks HIV replication and exhibits activity against wild-type HIV-1IIIB (subtype B, X4-tropic) and HIV-1 97USSN54 (subtype A, R5-tropic) with EC50s of 0.6 μM and 0.9 μM, respectively. Additionally, HIV-1 inhibitor-6 demonstrates inhibitory effects against various HIV strains that are resistant to existing therapies targeting reverse transcriptase, protease, integrase, and CCR5, with EC50s ranging from 0.9 to 1.5 μM. This compound is a valuable tool for researching HIV-1 mechanisms and therapeutic strategies. -
HIV Inhibitor
Decanoyl-RVKR-CMK TFA is a potent inhibitor of HIV-1, specifically targeting the over-expression of the gp160 protein, thereby blocking its processing. This compound demonstrates significant antiviral activity against HIV-1 replication, making it a valuable tool in the study of HIV biology and therapeutic development. Its application includes research focused on the mechanisms of HIV infection and potential therapeutic interventions. -
HIV Inhibitor
Schisantherin D is a dibenzocyclooctadiene lignan that exhibits significant anti-HIV activity with an EC50 of 0.5 μg/mL. This compound selectively inhibits endothelin receptor B (ETBR) and demonstrates hepatoprotective properties. Schisantherin D is valuable for research applications focused on HIV replication and the exploration of liver protective mechanisms. -
HIV/SARS-CoV Inhibitor
2-Hydroxyacetophenone is an inhibitor targeting HIV and SARS-CoV. This compound exhibits significant antiviral activity, making it a valuable tool for research in the development of therapeutic strategies against these viral infections. Additionally, it serves as a versatile building block for synthesis in various chemical applications. -
HIV-1 Inhibitor
Fipravirimat dihydrochloride is a potent inhibitor of HIV-1, demonstrating significant antiviral activity against this virus. This compound is valuable for research applications focused on HIV and AIDS, facilitating studies aimed at understanding viral replication mechanisms and testing therapeutic strategies. Its efficacy makes it a crucial tool for the development of new antiviral treatments. -
HIV Inhibitor
GSK2838232 is an inhibitor of HIV reverse transcriptase, displaying potent activity against a diverse array of HIV-1 isolates. This compound is crucial for studying HIV replication and has applications in antiviral drug development and research focused on HIV resistance mechanisms. Its effectiveness in inhibiting viral replication makes it a valuable tool for understanding the dynamics of HIV infections and testing therapeutic strategies. -
HIV-1 Inhibitor
Ingenol-3-palmitate is an ingenane diterpenoid that functions as a potent inhibitor of HIV-1, demonstrating an IC50 value of 4.1 nM. This compound, derived from the roots of Euphorbia ebracteolata, exhibits significant antiviral activity, making it a valuable tool in HIV research. Its mechanism of action can enhance understanding of viral replication and potential therapeutic strategies against HIV infection. -
HIV Inhibitor
Gomisin M2, a lignan derived from the fruits of Schisandra rubriflora, serves as an effective HIV inhibitor with an EC50 of 2.4 μM. In addition to its anti-HIV properties, Gomisin M2 demonstrates anti-cancer and anti-allergic activities, indicating its multifaceted biological potential. This compound may also offer valuable insights for research related to Alzheimer’s disease. -
HIV Inhibitor
Azulene, a bicyclic hydrocarbon, exhibits potent anti-HIV activity by targeting viral replication mechanisms. Isolated from chamomile oil, it serves as an important scaffold in medicinal chemistry, facilitating the design of new antiviral agents. Its unique structure and biological properties make it a valuable compound in HIV research and therapeutic development. -
Nucleoside Reverse Transcriptase Inhibitor
Rovafovir etalafenamide is a prodrug of the adenosine nucleotide analogue GS-9148, functioning as a nucleoside reverse transcriptase inhibitor (NRTI). It demonstrates significant potency against a range of NRTI-resistant HIV-1 mutations, making it an important tool in HIV research. Its effective anti-HIV-1 activity positions it as a valuable compound for studies aimed at understanding viral resistance mechanisms and the development of therapeutic strategies. -
HIV-1 Inhibitor
BDM-2 is a potent allosteric inhibitor of HIV-1 integrase, specifically targeting the IN-LEDGF interaction. With an IC50 of 47 nM, it exhibits significant anti-retroviral activity and an AC50 for IN multimerization activation of 20 nM. BDM-2 effectively disrupts the binding between the integrase catalytic core domain and the LEDGF/p75 integrase binding domain, with an IC50 of 0.15 μM. This compound demonstrates a high degree of selectivity and a favorable cytotoxicity profile, making it a valuable tool for HIV research.
